Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06062017
Other study ID # #23-381
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date May 2026

Study information

Verified date January 2024
Source Auburn University
Contact Nina L Stute, M.S.
Phone 9373071608
Email NLS0028@auburn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Compared with White Adults, Non-Hispanic Black Adults are at an elevated risk of developing cardiovascular disease (CVD) and end stage chronic-kidney disease (CKD), two of the leading causes of death in the United States. Inadequate hydration status is associated with risk factors for both CVD and CKD. Prior data show that Black individuals are less likely to be adequately hydrated when compared with their White counterparts. Further, socioeconomic factors have been shown to influence hydration practices. Inadequate hydration influences certain hormones that regulate blood volume and impact blood pressure, but increasing potassium intake may provide some positive effects on normalizing these hormones and blood pressure. Black adults, in particular, are more likely to consume less potassium, have inadequate hydration, and tend to have higher blood pressure. As such, there is a critical need for effective strategies to address racial disparities in hydration and resultant health consequences; as well as establish the role of socioeconomic factors contributing to hydration. Therefore, the investigators are seeking to test the investigators' central hypothesis that both water, and to a greater extent, water with a potassium supplement will improve hydration and cardiovascular health in young Black adults (n = 40, 20 females, 20 males). The investigators will assess measures of blood pressure, arterial stiffness, and biomarkers in the urine and blood samples prior to and following a 14-day hydration intervention of either a) bottled water or b) bottled water with potassium supplementation (2000mg potassium/day).


Description:

Compared with White adults, Non-Hispanic Black adults are at an elevated risk of developing cardiovascular disease (CVD) and end-stage chronic kidney disease (CKD) two of the leading causes of mortality in the United States (U.S.). Inadequate hydration status is associated with all-cause mortality and several risk factors for CVD and CKD including obesity, insulin resistance, hypertension, and metabolic syndrome. Prior data demonstrate Black American individuals are more likely to be hypohydrated (i.e., inadequately hydrated) when compared with White individuals. One study in emerging adults (18-25 years old) indicates that Black adults are more likely to be hypohydrated compared with White adults when assessed using gold-standard 24-hour urine collections. Socioeconomic factors influence hydration practices. For example, there are well-justified increased perceptions of unsafe tap water among racial and ethnic minorities. Indeed, the recent Flint, Michigan, and Jackson, Mississippi water crises have raised public awareness over these environmental injustices and ways to increase safe drinking water availability and access. However, there remains a critical need for empirical studies on 1) strategies to address racial disparities in hydration and resultant health consequences; and 2) the role socioeconomic factors in contributing to hydration. Importantly, hypohydration is associated with increased production of arginine vasopressin (AVP), a peptide hormone produced in the hypothalamus that influences body water balance via anti-diuretic effects. Plasma copeptin is an established surrogate marker of circulating AVP concentration. Plasma copeptin is associated with incident type 2 diabetes, metabolic syndrome, the progression of CKD, and CVD. Some, but not all, studies have demonstrated racial differences in circulating AVP/copeptin. Further, prior studies that aimed at increasing water resulted in reductions in copeptin and improvements in cardiometabolic health. For example, in a cohort with high plasma copeptin, increased water intake also reduced fasting plasma glucose. In a cohort of adults with overweight and obesity, increased water or low-calorie beverage intake reduced fasting plasma glucose and contributed to modest weight loss. Lastly, over 90% of adults do not meet recommendations for potassium intake. Importantly, potassium improves blood pressure (BP), particularly in Black adults, who tend to consume less potassium and have higher BP. Yet, there remains a knowledge gap regarding whether hydration intervention(s) inclusive of water (with or without) potassium could attenuate racial disparities in hydration status and circulating AVP/copeptin. Therefore, the investigators are seeking to test the investigators' central hypothesis that both water and water along with a potassium supplement (2000mg/day) will improve hydration and cardiovascular health in young Black adults (n = 40, 20 females, 20 males). The investigators will utilize three complementary specific aims to address the investigators' hypotheses: Aim 1: Determine whether water alone, or water with potassium supplementation improve hydration status and reduce circulating copeptin. The investigators hypothesize that two weeks of consuming water, and to a greater extent, water and potassium supplementation will improve hydration and renal biomarkers, including increased urine volume, and reduced urine specific gravity, urine osmolality, and plasma copeptin. Aim 2: Determine whether water and to a greater extent, water and potassium supplementation improve BP and vascular health. The investigators hypothesize that two weeks of consuming water or water and potassium supplementation will reduce resting laboratory BP and ambulatory BP (awake, asleep, and nocturnal BP dipping), and reduce arterial stiffness assessed via pulse wave velocity. Aim 3: Determine whether socioeconomic factors are associated with hydration perceptions, knowledge, and practices. The investigators hypothesize that area deprivation index (ADI, i.e., more deprivation) will be associated with hydration perceptions (e.g., greater distrust of tap water) and inadequate hydration assessed by self-reported fluid intake and urine-specific gravity. In summary, a knowledge gap remains in determining the underlying reasons for the consistently reported racial differences in hydration. To restate, the purpose of this study is to determine 1) whether prescribing water and/or water with potassium supplementation are efficacious at improving hydration and reducing plasma copeptin in Black adults; 2) the comparative effectiveness of water and potassium supplementation vs. water alone in improving fluid intake and hydration status; 3) whether improving hydration alone or in combination with supplemental potassium improves BP and vascular function in young Black adults; 4) Another area of innovation in the investigators' proposal is determining whether area deprivation index (ADI, i.e., more deprivation) is associated with and 4a) beliefs and practices around hydration and 4a) hydration status.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date May 2026
Est. primary completion date December 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Between the ages of 18-30 years - Resting blood pressure no higher than 150/90 mmHg - BMI below 35 kg/m2 - Free of any metabolic disease (e.g., diabetes) kidney disease, pulmonary disorders (e.g., COPD), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular), no autoimmune diseases, and no history of cancer. Exclusion Criteria: - Have any precluding medical conditions (i.e. hemophilia) or medication (Pradaxa, Eliquis, etc.) that prevent participants from giving blood. - Are currently pregnant or trying to become pregnant. - take any of the following medications that are contraindicated with potassium supplementation: - Renin-angiotensin-aldosterone system (RAAS) blockers: Candesartan , Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan - Non -steroidal anti-inflammatory medications: Aspirin, Ibuprofen, Naproxen - Non-selective beta-blockers: Pindolol, Penbutolol, Oxprenolol, Propranolol, Nadolol, Sotalol, Timolol, Tertatolol - Calcineurin inhibitors: Cyclosporine - Heparin (or other blood thinning medications)

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Water and Potassium supplementation
20 Participants will be given cases of water and instructed to drink at least an extra 1L per day. Additionally, participants will be given 2000 mg of potassium via potassium citrate powder.
Other:
Water alone
20 Participants will be given cases of water and instructed to drink at least an extra 1L per day.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Auburn University Indiana University

References & Publications (6)

Brooks CJ, Gortmaker SL, Long MW, Cradock AL, Kenney EL. Racial/Ethnic and Socioeconomic Disparities in Hydration Status Among US Adults and the Role of Tap Water and Other Beverage Intake. Am J Public Health. 2017 Sep;107(9):1387-1394. doi: 10.2105/AJPH.2017.303923. Epub 2017 Jul 20. — View Citation

Fuller-Rowell TE, Nichols OI, Robinson AT, Boylan JM, Chae DH, El-Sheikh M. Racial disparities in sleep health between Black and White young adults: The role of neighborhood safety in childhood. Sleep Med. 2021 May;81:341-349. doi: 10.1016/j.sleep.2021.03.007. Epub 2021 Mar 12. — View Citation

Onufrak SJ, Park S, Sharkey JR, Merlo C, Dean WR, Sherry B. Perceptions of tap water and school water fountains and association with intake of plain water and sugar-sweetened beverages. J Sch Health. 2014 Mar;84(3):195-204. doi: 10.1111/josh.12138. — View Citation

Onufrak SJ, Park S, Sharkey JR, Sherry B. The relationship of perceptions of tap water safety with intake of sugar-sweetened beverages and plain water among US adults. Public Health Nutr. 2014 Jan;17(1):179-85. doi: 10.1017/S1368980012004600. Epub 2012 Oct 26. — View Citation

Park S, Onufrak SJ, Cradock AL, Patel A, Hecht C, Blanck HM. Perceptions of Water Safety and Tap Water Taste and Their Associations With Beverage Intake Among U.S. Adults. Am J Health Promot. 2023 Jun;37(5):625-637. doi: 10.1177/08901171221150093. Epub 2023 Jan 6. — View Citation

Robinson AT, Linder BA, Barnett AM, Jeong S, Sanchez SO, Nichols OI, McIntosh MC, Hutchison ZJ, Tharpe MA, Watso JC, Gutierrez OM, Fuller-Rowell TE. Cross-sectional analysis of racial differences in hydration and neighborhood deprivation in young adults. Am J Clin Nutr. 2023 Oct;118(4):822-833. doi: 10.1016/j.ajcnut.2023.08.005. Epub 2023 Aug 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Gut microbiome A fecal sample will be obtained and subjected to the isolation of microbial DNA from the fecal sample. High-throughput sequencing of the extracted DNA will be done using 16S rRNA gene sequencing Change score from habitual consumption to after the hydration interventions (2 weeks)
Other Hemoglobin Whole blood samples will be analyzed for hemoglobin concentration (HemoCue, radiometer) Change score from habitual consumption to after the hydration interventions (2 weeks)
Other Hematocrit Whole blood samples will be analyzed for hematocrit as a percentage (Thermo Hematocrit Microcentrifuge). Change score from habitual consumption to after the hydration interventions (2 weeks)
Other Physical activity Participants will wear an ActiGraph GT3X accelerometer for 14 days to objectively quantify steps taken per day. Pre-intervention (intake visit)
Other Area deprivation index Investigators will measure participant's area deprivation index (ADI) based on their self-reported zip code. The ADI is a multidimensional assessment of a region's socioeconomic conditions. It is used to measure and quantify the level of deprivation or disadvantage experienced by residents in a specific geographical area. The composite score will be standardized to have a mean of 100 and a standard deviation of 20 to assist interpretation. Pre-intervention (intake visit)
Other Blood pressure reactivity responses The investigators will measure systolic and diastolic pressure using photoplethysmography at the finger and manually measure brachial pressures in millimeters of mercury. Systolic and diastolic blood pressure will be assessed at rest and during a cold pressor test. Blood pressure reactivity will be expressed as a change in pressure (mmHg) from baseline to the last 30 seconds of the cold pressor test. Change score from habitual consumption to after the hydration interventions (2 weeks)
Primary Urine specific gravity 24 urine samples will be aliquoted and assessed for urine specific gravity (unitless) Change score from habitual consumption to after the hydration interventions (2 weeks)
Primary Urine osmolality 24 urine samples will be aliquoted and assessed for urine osmolality in mOsm/kg (AI Osmometer 3D3) Change score from habitual consumption to after the hydration interventions (2 weeks)
Primary Urine flow rate 24 urine samples will be assessed for urine flow rate based on urine volume and self-reported collection time (ml/min). Change score from habitual consumption to after the hydration interventions (2 weeks)
Primary Plasma copeptin Plasma copeptin concentration (picomoles per liter) from a resting blood draw Change score from habitual consumption to after the hydration interventions (2 weeks)
Primary 24-hour ambulatory blood pressure Participants will wear an Oscar2 (with SphygmoCor) ambulatory blood pressure monitor on their upper arm for up to 24-hours preceding their study visit to measure systolic and diastolic blood pressure. The purpose of the ambulatory blood pressure monitoring is to determine blood pressure regulation over an entire day. This blood pressure monitor will be set to automatically take blood pressure every 20 minutes. The monitor records and saves each blood pressure measurement automatically. Change score from habitual consumption to after the hydration interventions (2 weeks)
Primary Pulse wave velocity The investigators will use the SphygmoCor XCEL system to assess pulse wave velocity (PWV meters per second). A high-fidelity transducer is used to obtain the pressure waveform at the carotid pulse. Distances from the carotid artery sampling site to the femoral artery (upper leg instrumented with a thigh cuff for oscillometric sphygmomanometry), and from the carotid artery to the suprasternal notch will be recorded. PWV will be expressed as cm/s. Change score from habitual consumption to after the hydration interventions (2 weeks)
Primary Pulse wave analysis The investigators will use the SphygmoCor XCEL system to assess pulse wave analysis (PWA) The sampling site is the brachial artery (upper alarm instrumented with a cuff for oscillometric sphygmomanometer). PWA will be expressed as a percentage (calculated as augmentation pressure divided by the pulse pressure). Change score from habitual consumption to after the hydration interventions (2 weeks)
Primary Brachial blood pressure Seated rachial blood pressure will be measured triplicate after at least 5 minutes of rest using an oscillometric device (Suntech CT 40) Change score from habitual consumption to after the hydration interventions (2 weeks)
Secondary Kidney blood velocity Renal and segmental artery blood velocity will be assessed in the decubitis position using a high-frequency ultrasound probe, typically in the range of 3-5 MHz.Using Spectral Doppler, the peak systolic velocity (PSV) in the renal and segmental arteries will be measured. Change score from habitual consumption to after the hydration interventions (2 weeks)
Secondary Plasma Osmolality Researchers will analyze blood samples for osmolarity (AI Osmometer 3D3) Change score from habitual consumption to after the hydration interventions (2 weeks)
Secondary Plasma electrolytes Researchers will analyze plasma samples for electrolytes (Na, K, Cl) concentration using the SmartLyte Electrolyte Analyzer. The unit of measure for Na, K, and Cl is millimoles per liter (mmol/L). Change score from habitual consumption to after the hydration interventions (2 weeks)
Secondary Blood glucose Researchers will analyze whole blood samples for blood glucose concentration in milligrams per deciliter using Cholestech benchtop analyzer Change score from habitual consumption to after the hydration interventions (2 weeks)
Secondary Objective sleep duration Philips actiwatch spectrum will be used to quantify sleep duration in hours. Participants will wear the watch units for 14 days. The investigators will assess sleep duration and cross-check actigraphy wear times with a sleep diary. Pre-intervention (14 days)
Secondary Objective sleep efficiency Philips actiwatch spectrum will be used to quantify the percentage of time in bed actually spent sleeping to calculate sleep efficiency. Pre-intervention (14 days)
Secondary Subjective sleep duration The investigators will use the Pittsburgh Sleep Quality Index (PSQI) to assess sleep duration reflective of the one-month period leading into the study. The global PSQI score can range from 0 to 21 points, however, this outcome specifically refers to self-reported sleep duration in hours. Change score from habitual consumption to after the hydration interventions (2 weeks)
Secondary Subjective sleep quality The investigators will use the Pittsburgh Sleep Quality Index (PSQI) to assess perceived sleep quality reflective of the one-month period leading into the study. The global PSQI score can range from 0 to 21 points. Change score from habitual consumption to after the hydration interventions (2 weeks)
Secondary Urine electrolytes Researchers will analyze 24-hour urine samples for electrolytes (Na, K, Cl) content using the SmartLyte Electrolyte Analyzer. The unit of measure for Na, K, and Cl is milliequivalents (mEq). Change score from habitual consumption to after the hydration interventions (2 weeks)
Secondary Inflammatory cytokine responses Plasma will be used for a multiplex to measure inflammatory cytokines tumor necrosis factor-alpha, interleukin-6, monocyte chemoattractant protein-1, and interleukin-1. These biomarkers will be measured by enzyme-linked immunosorbent assays (ELISAs) from R&D. Change score from habitual consumption to after the hydration interventions (2 weeks)
Secondary Dietary intake The investigators will instruct participants to complete a diet log for 3 days which will be operationalized with Nutrition Data System for Research (NDSR). Change score from habitual consumption to after the hydration interventions (2 weeks)
See also
  Status Clinical Trial Phase
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT05997303 - Continuous Norepinephrine Administration and Blood Pressure Stability During Anesthetic Induction N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT03918486 - Caretaker vs. Routine Blood Pressure Sphygmomanometer
Completed NCT03410342 - The Effects of Types of Fruits and Vegetables on Vascular Function N/A
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT04087070 - Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
Completed NCT03294928 - Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers N/A
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03997461 - Comparison of Arterial Tonometry Sensor With Standard Oscillometric Blood Pressure Monitoring Device N/A
Completed NCT03290716 - Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China N/A
Recruiting NCT05196048 - Blood Pressure Sensor of Watch-type Device With ECG Technology
Recruiting NCT06460233 - Blood Pressure Changes After Bariatric Surgery
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Completed NCT02924454 - Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol. Phase 4
Completed NCT02451059 - Reducing Socioeconomic Disparities in Health at Pediatric Visits N/A
Active, not recruiting NCT02670967 - Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials N/A
Completed NCT02239744 - Intervention Study on the Health Impact of Air Filters in Chinese Adults N/A
Completed NCT02271633 - Nitrate Supplementation; Source Phase 4